Key Events This Week
25 May: New 52-week and all-time high at Rs.1,137.05
26 May: Upper circuit hit, closing at Rs.1,192.95
27 May: New 52-week and all-time high at Rs.1,221.80 with upper circuit
29 May: New 52-week and all-time high at Rs.1,282.85 with upper circuit
Monday, 25 May 2026: New 52-Week and All-Time High at Rs.1,137.05
Venus Remedies Ltd opened the week on a strong note, surging 5.00% to close at Rs.1,137.05, marking a new 52-week and all-time high. This gain outpaced the Sensex’s 1.23% rise, reflecting robust buying interest. The stock’s momentum was supported by its position above all key moving averages and a 10.24% return over the prior two sessions. Institutional investors increased their stake by 0.72% in the previous quarter, signalling growing confidence. The company’s net-debt-free status and a 198.70% growth in profit after tax over six months underpinned this rally.
Tuesday, 26 May 2026: Upper Circuit at Rs.1,192.95 Amid Strong Buying
On 26 May, Venus Remedies Ltd hit the upper circuit limit of 5%, closing at Rs.1,192.95. The stock outperformed the Pharmaceuticals & Biotechnology sector, which declined 0.11%, and the Sensex, which fell 0.08%. The total traded volume was approximately 1.48 lakh shares, generating a turnover of Rs.17.18 crore. Despite a slight intraday pullback, the stock maintained its position above all key moving averages. Financially, the company reported a 96.37% surge in operating profit in the December 2025 quarter and a return on capital employed of 13.99%, supporting the sustained price strength.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Wednesday, 27 May 2026: New 52-Week High at Rs.1,221.80 with Upper Circuit
Venus Remedies Ltd continued its strong rally, hitting a new 52-week and all-time high of Rs.1,221.80, closing with a 5.00% gain and triggering the upper circuit. This marked the fourth consecutive day of gains, delivering an 18.46% return over this period. The stock outperformed the Sensex, which declined 0.19%. Technical indicators such as MACD, Bollinger Bands, and KST signalled bullish momentum. The company’s financials remained robust, with a 193.78% net profit growth in the December 2025 quarter and a price-to-book ratio of 2.6, reflecting premium valuation supported by earnings growth.
Thursday, 28 May 2026: No Trading Data Available
There was no trading data available for Venus Remedies Ltd on 28 May 2026.
Friday, 29 May 2026: New 52-Week and All-Time High at Rs.1,282.85
Venus Remedies Ltd capped the week by hitting a fresh 52-week and all-time high of Rs.1,282.85, closing with a 5.00% gain. This extended the winning streak to five consecutive trading days, delivering a cumulative return of 24.38%. The stock outperformed the Pharmaceuticals & Biotechnology sector by 4.61% and the Sensex by a wide margin. Financially, the company reported record quarterly net sales of Rs.259.40 crore and a PBDIT of Rs.63.42 crore. Return on capital employed reached 19.85%, and return on equity stood at 15.5%, underscoring efficient capital utilisation. Technical indicators remained strongly bullish, supported by rising delivery volumes and institutional participation.
Thinking about Venus Remedies Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-25 | Rs.1,137.05 | +5.00% | 35,849.10 | +1.23% |
| 2026-05-26 | Rs.1,192.95 | +4.93% | 35,787.99 | -0.17% |
| 2026-05-27 | Rs.1,221.80 | +2.40% | 35,899.16 | +0.31% |
| 2026-05-29 | Rs.1,282.85 | +5.00% | 35,417.64 | -1.34% |
Key Takeaways
Strong Price Momentum: Venus Remedies Ltd recorded a robust 18.46% weekly gain, hitting multiple new 52-week and all-time highs, driven by consistent upper circuit hits and sustained buying pressure.
Financial Strength: The company’s net-debt-free status, 198.70% PAT growth over six months, and record quarterly sales and profits underpin the stock’s rally, reflecting operational excellence and capital efficiency.
Technical Indicators: All key moving averages and momentum indicators such as MACD, Bollinger Bands, and KST signal a strong bullish trend, supported by rising delivery volumes and institutional participation.
Institutional Confidence: A 0.72% increase in institutional shareholding to 4% indicates growing confidence from sophisticated investors, complementing the stock’s fundamental and technical strength.
Sector Outperformance: The stock consistently outperformed the Pharmaceuticals & Biotechnology sector and the Sensex, highlighting its relative strength amid mixed broader market conditions.
Conclusion
Venus Remedies Ltd’s exceptional weekly performance, marked by multiple new highs and upper circuit hits, reflects a confluence of strong financial results, positive technical momentum, and increasing institutional interest. Despite a mixed broader market environment, the stock’s sustained outperformance underscores its resilience and growth potential within the Pharmaceuticals & Biotechnology sector. Investors should monitor volume trends and technical signals closely as the stock navigates its current bullish phase, while remaining mindful of the inherent volatility associated with its micro-cap status.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
